Key result
An ssDNA aptamer reduced beta1-AAB induced cell toxicity and neutralized chronotropic beta1-AAB function in a dose-dependent manner in vitro.
Why the study?
Does an ssDNA aptamer targeting beta1-AABs reduce cell toxicity and neutralize chronotropic responses in cultured neonatal rat cardiomyocytes exposed to autoantibodies from cardiomyopathy patients?
Does an ssDNA aptamer targeting beta1-AABs reduce cell toxicity and neutralize chronotropic responses in cultured neonatal rat cardiomyocytes exposed to autoantibodies from cardiomyopathy patients?
An ssDNA aptamer successfully neutralized beta1-adrenoceptor autoantibodies from cardiomyopathy patients in vitro, preventing cell toxicity and chronotropic responses.
No takes yet. Share an insight, caveat, or question.
No clinical adoption yet; leaves open whether ssDNA aptamers can target beta1-AABs in cardiomyopathy.
Haberland et al. (2011) studied Cardiomyopathies (idiopathic dilated cardiomyopathy, Chagas' cardiomyopathy, peripartum cardiomyopathy). ssDNA aptamer targeting human beta1-AABs vs. Complementary (antisense) aptamer and control scrambled-sequence aptamer was evaluated on beta1-AAB induced cell toxicity and chronotropic cell responses in cultured neonatal rat cardiomyocytes. An ssDNA aptamer reduced beta1-AAB induced cell toxicity and neutralized chronotropic beta1-AAB function in a dose-dependent manner in vitro.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: